3 million cataract surgeries per year(US) let's say 3 million (ROW) 6 million times let's assume $40 per script....240 Million@ 5 times sales.....let's throw in 100 million for blepharitis and 100 million for BC(tho this is a huge underestimate) around 1.5 BILLION dollar buyout of course very crude estimate but you get the picture massively undervalued!!! Assuming positive phase 3.
Well sounds great, but the PPS better start taking a run up to have a buyout price anywhere near where you are suggesting. I am not sure if I have seen any buyout offers that have come in much above 100% of the share price at the time of the offer, which at todays price of 32 cents is not much. Right now we would be fortunate to get a dollar a share. I guess it is a long-term hold and see at this point.
If the bleph trial results, which are due at any moment, are good, the runup will be more like a gap up. Then the offer comes on top of that new mesa. P.S. the durasite 2 patent allowance should be announced too.